Feb 19 2021 Read 3581 Times
Three Innovate UK grants have been awarded to scientists at the University of Liverpool to develop anti-viral technology that will limit the transmission of SARS-CoV-2 (Covid-19) from touching contaminated surfaces in areas such as hospitals, train stations or restaurants and shops.
Researchers from the University’s Open Innovation Hub for Antimicrobial Surfaces will work alongside local industry and partners targeting three main applications: anti-viral coatings to create reusable face visors and goggles with high optical performance; a transparent anti-viral touch screen coating for ticket machines used widely in public transport and healthcare; and a point-of-sale cleansing system for the retail sector to rapidly disinfect card readers after every use.
COVID-19 infection rate plummets in England, says Imperial College study
kingdomfm.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kingdomfm.co.uk Daily Mail and Mail on Sunday newspapers.
Lockdown is working! COVID-19 infection rate plummets in England
msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
AGILE is a UK clinical trial platform for rapid clinical evaluation of potential COVID treatments.
A major clinical trial platform designed for the rapid clinical evaluation of potential COVID-19 treatments has received a multi-million pound funding boost to aid its expansion.
The AGILE testing platform, co-led by researchers at the NIHR Southampton Clinical Trials Unit at the University of Southampton, has received £3.2m from the UK government’s Department of Health and Social Care to fast track the clinical trials of innovative treatments against the coronavirus.
Awarded by the Medical Research Council and co-funded through the National Institute of Health Research (NIHR), this new money will allow AGILE’s activity to be expanded nationally into five UK centres, and complements funding from the Wellcome Trust and UNITAID in addition to funding announcements from industry.